Close Menu
NEW YORK (GenomeWeb News) - Ipsogen said today it has granted Warnex exclusive rights to market its JAK2 leukemia diagnostic test in Canada.
 
The test is based on variations in the JAK2 gene, for which Ipsogen holds intellectual property rights. It detects certain mutations in the gene linked to myeloproliferative disorders, including myelogenous leukemia, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. 
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

Newsweek discusses the privacy issues raised by digital medicine.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.